BCPC Stock Analysis: Balchem | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 5.366m USD | 12M Return: 2.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.6M
EPS Trend: 97.3%
Qual. Beats: 0
Rev. Trend: 90.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Balchem Corporation is a U.S.-based specialty ingredient manufacturer operating three core segments: Human Nutrition and Health (food and beverage ingredients such as spray-dried powders, microencapsulated nutrients, vitamin K2, and choline products), Animal Nutrition and Health (microencapsulated feed supplements, chelated minerals, methylsulfonylmethane, and choline chloride for livestock and companion animals), and Specialty Products (ethylene oxide and propylene oxide for sterilization and fumigation, plus chelated minerals for high-value crops). The company serves nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets globally, distributing through a direct sales force as well as independent distributors and sales agents. Founded in 1967 and headquartered in Montvale, New Jersey, Balchem trades on NASDAQ under the ticker BCPC.
Operating within the specialty chemicals sub-industry, Balchems business model centers on proprietary ingredient technologies-particularly microencapsulation and chelation-that enable controlled release and improved nutrient absorption. Diversification across human, animal, and industrial end-markets helps the company offset cyclical demand swings in any single application area.
- EPA tightens ethylene oxide rules on medical sterilization segment
- Functional food demand lifts vitamin K2 and choline sales
- Dairy industry health trends boost ruminant nutrition revenue
| Net Income: 158.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 22.36% < 20% (prev 20.81%; Δ 1.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 220.2m > Net Income 158.1m |
| Net Debt (127.6m) to EBITDA (270.7m): 0.47 < 3 |
| Current Ratio: 2.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.3m) vs 12m ago -1.59% < -2% |
| Gross Margin: 36.27% > 18% (prev 35.55%; Δ 0.73% > 0.5%) |
| Asset Turnover: 63.86% > 50% (prev 59.63%; Δ 4.23% > 0%) |
| Interest Coverage Ratio: 20.49 > 6 (EBIT TTM 213.1m / Interest Expense TTM 10.4m) |
| A: 0.14 (Total Current Assets 388.9m - Total Current Liabilities 152.5m) / Total Assets 1.69b |
| B: 0.69 (Retained Earnings 1.16b / Total Assets 1.69b) |
| C: 0.13 (EBIT TTM 213.1m / Avg Total Assets 1.66b) |
| D: 3.14 (Book Value of Equity 1.29b / Total Liabilities 408.6m) |
| Altman-Z'' = 7.32 = AAA |
| DSRI: 1.08 (Receivables 154.2m/130.4m, Revenue 1.06b/964.5m) |
| GMI: 0.98 (GM 35.55% / 36.27%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.10 (Revenue 1.06b / 964.5m) |
| TATA: -0.04 (NI 158.1m - CFO 220.2m) / TA 1.69b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 13, 2026, the stock is trading at USD 162.15 with a total of 243,643 shares traded. Over the past week, the price has changed by -3.94%, over one month by -1.75%, over three months by -8.14% and over the past year by +2.58%.
Current recommended Stop Loss: 156.60 (which is 3.4% or 1.5 ATR below the current price).
Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 200.8 | 23.8% |
P/E Trailing = 34.3642
P/E Forward = 31.0559
P/S = 5.075
P/B = 4.2228
P/EG = 3.881
Revenue TTM = 1.06b USD
EBIT TTM = 213.1m USD
EBITDA TTM = 270.7m USD
Long Term Debt = 169.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.65m USD (from shortTermDebt, last quarter)
Debt = 200.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.7m
Net Debt = 127.6m USD (calculated: Debt 200.4m - CCE 72.9m)
Enterprise Value = 5.49b USD (5.37b + Debt 200.4m - CCE 72.9m)
Interest Coverage Ratio = 20.49 (Ebit TTM 213.1m / Interest Expense TTM 10.4m)
EV/FCF = 31.22x (Enterprise Value 5.49b / FCF TTM 176.0m)
FCF Yield = 3.20% (FCF TTM 176.0m / Enterprise Value 5.49b)
FCF Margin = 16.64% (FCF TTM 176.0m / Revenue TTM 1.06b)
Net Margin = 14.95% (Net Income TTM 158.1m / Revenue TTM 1.06b)
Gross Margin = 36.27% ((Revenue TTM 1.06b - Cost of Revenue TTM 673.8m) / Revenue TTM)
Gross Margin QoQ = 37.34% (prev 35.62%)
Tobins Q-Ratio = 3.24 (Enterprise Value 5.49b / Total Assets 1.69b)
Interest Expense / Debt = 5.19% (Interest Expense 10.4m / Debt 200.4m)
Taxrate = 22.36% (45.5m / 203.6m)
NOPAT = 165.5m (EBIT 213.1m * (1 - 22.36%))
Current Ratio = 2.55 (Total Current Assets 388.9m / Total Current Liabilities 152.5m)
Debt / Equity = 0.16 (Debt 200.4m / totalStockholderEquity, last quarter 1.29b)
Debt / EBITDA = 0.47 (Net Debt 127.6m / EBITDA 270.7m)
Debt / FCF = 0.72 (Net Debt 127.6m / FCF TTM 176.0m)
Total Stockholder Equity = 1.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.55% (Net Income 158.1m / Total Assets 1.69b)
RoE = 12.38% (Net Income TTM 158.1m / Total Stockholder Equity 1.28b)
RoCE = 14.74% (EBIT 213.1m / Capital Employed (Equity 1.28b + L.T.Debt 169.0m))
RoIC = 11.09% (NOPAT 165.5m / Invested Capital 1.49b)
WACC = 6.74% (E(5.37b)/V(5.57b) * Re(6.84%) + D(200.4m)/V(5.57b) * Rd(5.19%) * (1-Tc(0.22)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -0.26%
[DCF] Terminal Value 77.97% ; FCFF base≈165.9m ; Y1≈190.2m ; Y5≈279.9m
[DCF] Fair Price = 127.1 (EV 4.21b - Net Debt 127.6m = Equity 4.08b / Shares 32.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.33 | EPS CAGR: 12.08% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.90 | Revenue CAGR: 4.83% | SUE: 0.84 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.43 | Chg30d=+1.42% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.50 | Chg30d=+1.01% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=-0.02% | Revisions=+0% | GrowthEPS=+10.4% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=6.11 | Chg30d=+0.59% | Revisions=+25% | GrowthEPS=+7.5% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +38% (up=4, down=1)